03:06:10 EST Sun 08 Dec 2019
Enter Symbol
or Name

Login ID:
Cognetivity Neurosciences Ltd
Symbol CGN
Shares Issued 41,447,022
Close 2018-09-10 C$ 0.42
Recent Sedar Documents

Cognetivity starts trial for dementia detection tech

2018-09-10 10:27 ET - News Release

Dr. Sina Habibi reports


Cognetivity Neurosciences Ltd. has started its key clinical validation trial. The trial is being carried out in relation to the detection of cognitive performance in Alzheimer's and pre-Alzheimer's patients and will take place in London, England.

This trial is part of the established process toward gaining clinical regulatory approval for the company's proprietary integrated cognitive assessment (ICA) platform, which will allow the ICA to be used in clinical environments. The ICA's attributes, sensitivity and use of artificial intelligence make it a highly promising tool for allowing the screening of large numbers of people for early-stage cognitive impairment associated with conditions such as Alzheimer's and other related diseases including dementia.

The trial is being conducted at the South London and Maudsley (SLaM) NHS Foundation Trust, which has the largest mental health research and development portfolio in the United Kingdom, and in conjunction with the Institute of Psychiatry, Psychology & Neuroscience at King's College London. The principal investigator of the study is Prof. Dag Aarsland, chair of old age psychiatry at King's College London, a notable global researcher in the field.

Prof. Aarsland commented: "We are very pleased to be adding this study to our portfolio of trials and working with Cognetivity on validating this exciting technology. Early detection of cognitive impairment, potentially linked to dementia, is so important. While a diagnosis of dementia is devastating, for many people getting an early diagnosis can open the doors to treatment and support and also enable people to make decisions and plan for the future. Importantly, emerging pharmacological treatments for Alzheimer's and other diseases that cause dementia are most likely to be targeted during the very earliest stages of the disease, giving even greater impetus to the need to diagnose early."

Cognetivity's chief executive officer and director, Dr. Sina Habibi, said: "We are delighted to be starting this trial which is the result of a lot of hard work by our team. This is an important step in delivering a tool which we believe can help an enormous number of people, by allowing the earlier detection of the cognitive impairment associated with dementias and other conditions -- a vital step in providing the best care, improving outcomes for patients and massively reducing payer costs. While we have already experimentally demonstrated the platform's ability to detect the early cognitive signs of Alzheimer's disease, the next notable stage is to go through the formal process of regulatory approval, which is required to show that the technology can be used safely in a clinical environment. On successful conclusion of this trial we will be able to submit our results for regulatory approval in the USA and Europe. This will in turn allow us to fully commercialize our ICA platform and enable it to begin being used as a clinical tool by medical professionals."

About Cognetivity Neurosciences Ltd.

Cognetivity Neurosciences is a technology company developing a cognitive testing platform, the integrated cognitive assessment (ICA), for use in medical and commercial environments. Cognetivity Neurosciences' ICA uses artificial intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity Neurosciences aims to develop the ICA through planned clinical studies to the market in North America and Europe.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.